Hypothalamic-pituitary-adrenal axis suppression in systemic glucocorticoid-treated infantile hemangiomas

Archives of Dermatology

Volumn 145, Issue 3, 2009, Pages 319-320

  Sidbury, Robert ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID; PREDNISONE; PROPRANOLOL;

ADRENAL CORTEX INSUFFICIENCY; APPETITE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CORTICOTROPIN TEST; DERMATOMYCOSIS; DRUG OVERDOSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GROWTH; HEMANGIOMA; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS PITUITARY ADRENAL AXIS SUPPRESSION; INFANT; INFANTILE HEMANGIOMA; IRRITABILITY; LOW DRUG DOSE; MOON FACE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

GLUCOCORTICOIDS; HEMANGIOMA; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFANT; PITUITARY-ADRENAL SYSTEM; SKIN NEOPLASMS;

EID: 62649155781     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.576     Document Type: Review

References (12)

1. Enjolras O, Mulliken JB. Vascular tumors and vascular malformations. Adv Dermatol. 1997;13:375-423.
2. Frieden IJ, Eichenfield LF, Esterly NB, et al; American Academy of Dermatology Guidelines/Outcomes Committee. Guidelines of care for hemangiomas of infancy. J Am Acad Dermatol. 1997;37(4):631-637.
3. Bennett ML, Fleischer AB Jr, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol. 2001;137(9):1208-1213.
4. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticoste- roid therapy for problematic hemangiomas. Plast Reconstr Surg. 1999;104 (6):1616-1623.
5. Lomenick JP, Reifschneider KL, Lucky AW, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009;145(3):262-266.
6. Leaute-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, TaTeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358 (24):2649-2651.
7. Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas-a retrospective study. Pediatr Dermatol. 2006;23(2):169-174.
8. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high dose pulse corticoste- roids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6):e1239-e1247.
9. George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocor- ticosteroid therapy in infants with hemangiomas. Arch Dermatol. 2004;140 (8):963-969.
10. Agwu JC, Spoudeas H, Hindmarsh PC, et al. Tests for adrenal insufficiency. Arch Dis Child. 1999;80(4):330-333.
11. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367.
12. Horii KA, Simon SD, Liu DY, et al. Atopic dermatitis in children in the United States, 1997-2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007;120(3):e527-e534.